Cases of motor neuron diseases — including amyotrophic lateral sclerosis (ALS), the most common of these — are increasing in European countries. A study suggests the reason is not solely because of an aging population, though more people are living longer and neurodegenerative diseases are more common in older…
Motor neuron diseases are on the increase in Europe, study finds
Masitinib treatment was linked to a nearly doubled five-year survival rate among people with amyotrophic lateral sclerosis (ALS), with higher survival rates seen among patients with slower disease progression and those who started treatment before experiencing a complete loss of functionality. That’s according to new analyses from the…
Neurosense Therapeutics said it recently held a “constructive” meeting with Health Canada to discuss potential regulatory pathways for PrimeC, its experimental oral therapy for amyotrophic lateral sclerosis (ALS). The meeting focused on the company’s proposed new drug submission (NDS) strategy and the clinical, biomarker, and long-term outcomes data…
Last summer, a large limb on our old mountain ash died, and this spring, our teenage son cut it off, leaving only one limb coming out of the stump of a once beautiful tree. “Is it time to take it down?” I asked my husband, Todd. “I think so,” he…
Researchers using a fish model of amyotrophic lateral sclerosis (ALS) found that damage to the cerebellum — a brain region not traditionally associated with ALS — begins before motor symptoms emerge. This damage appears to be driven by reduced levels of PAICS, an enzyme involved in the production of…
A team at Stanford University has received a $13 million grant to uncover previously unknown genetic causes of amyotrophic lateral sclerosis (ALS), with the goal of identifying targets for future treatments. The grant, awarded by the California Institute for Regenerative Medicine (CIRM) to a team led by Stanford…
The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating misleading results, a study found. The researchers focused on analysis of the ALS Functional…
Two leaders at Brainstorm Cell Therapeutics, which is developing the experimental cell-based therapy NurOwn (debamestrocel) for people with amyotrophic lateral sclerosis (ALS), have published a paper calling on the U.S. Food and Drug Administration (FDA) to modernize its review process for experimental therapies for ALS and other…
Several nonprofits are uniting to fund new research aimed at identifying targets for the treatment of amyotrophic lateral sclerosis (ALS). The new initiative will be led by the Allen Institute, a nonprofit medical research organization, through its Brain Health Accelerator — a research initiative to study neurodegenerative diseases. The…
My husband, Todd, and I just finished watching the TV series “Person of Interest,” about a type of super artificial intelligence (AI) that predicts crime. The series, which ran from 2011 to 2016, was prescient about current issues resulting from AI and mass surveillance. In the penultimate episode, one of…
Recent Posts
- How new gene therapies are transforming genetic testing for ALS
- A trip to the ER makes me thankful I still have my parenting partner
- PBS documentary on runner with ALS explores identity, caregiving
- A new wheelchair means making adjustments mentally and physically
- Real-world study sheds new light on safety of approved ALS drug